Compare Smith & Nephew plc (SNN) vs Direxion Daily FTSE China Bull 3x Shares (YINN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Smith & Nephew plc vs Direxion Daily FTSE China Bull 3x Shares — how do they compare? Smith & Nephew plc trades at $27.24 (market cap $11.10B), while Direxion Daily FTSE China Bull 3x Shares trades at $25.27 (market cap $560.32M). The key difference: Smith & Nephew plc is far larger — about 19.8× Direxion Daily FTSE China Bull 3x Shares's market cap, and Smith & Nephew plc pays a 2.95% dividend while Direxion Daily FTSE China Bull 3x Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Smith & Nephew plc for 121 Days and Direxion Daily FTSE China Bull 3x Shares for 25 Days on average.
| SNN | YINN | |
|---|---|---|
Market Cap | $11.10B | $560.32M |
Volume | 1,051,703 | 1,009,521 |
Sector | Health | Leveraged / Inverse |
52-Week High | $37.17 | $52.69 |
52-Week Low | $26.42 | $21.45 |
Typical Hold Time | 121 Days | 25 Days |
Enterprise Value | $14.13B | — |
Dividend Yield | 2.95% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNN trades at $26.96, up 0.26% on the day, but near its 52-week low amid a bearish technical signal. Recent earnings have mostly beaten expectations, with Q2 2026 EPS of $0.946 exceeding the $0.939 estimate. Revenue grew to $6.16B in 2025, and net income margin improved to 10.08%. The company continues to launch new medical products, such as the EVOS PELVIC System, to drive growth.
The outlook is mixed; strong fundamentals and product innovation support long-term value, but near-term price pressure and analyst caution pose risks. Investors should weigh robust profitability against competitive threats and recent management changes.
YINN is trading at $25.27, up 7.26% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The stock lacks disclosed fundamental ratios such as P/E and P/S, and recent news highlights China's economic policies and energy sector dynamics, which may influence its performance. Support is clustered around $23, with resistance at $24.
The outlook remains cautious due to bearish technicals and limited fundamental visibility. Risks include reliance on Chinese economic conditions and potential regulatory changes. Investment opportunities hinge on improved earnings transparency and positive shifts in market sentiment, but current data suggests a neutral to bearish stance for near-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →About Direxion Daily FTSE China Bull 3x Shares
YINN is a leveraged ETF that seeks daily investment results, before fees and expenses, of 300% (3x) of the daily performance of the FTSE China 50 Index. It is a tactical instrument designed for sophisticated traders seeking to magnify short-term bullish views on large-cap Chinese equities, primarily those trading on the Hong Kong Stock Exchange.
Read more on YINN →
